Table 1 The baseline and clinical characteristics of HCC patients in the training and validation cohorts
Clinical parameters | Training cohort (n = 482) | Validation cohort (n = 216) | P |
|---|---|---|---|
Gender (male/female) | 404 (83.8%)/78 (16.2%) | 185 (85.6%)/31 (14.4%) | 0.538 |
Age (> 60/ ≤ 60 years) | 369 (76.6%)/113 (23.4%) | 162 (75.0%)/54 (25.0%) | 0.376 |
HBsAg (positive/negative) | 417 (86.5%)/65 (13.5%) | 187 (87.0%)/29 (13.0%) | 0.868 |
HBV-DNA (≥ 103/ < 103 copies/mL) | 261 (54.2%)/221 (45.8%) | 107 (49.5%)/109 (50.5%) | 0.282 |
HBeAg (positive/negative) | 97 (20.1%)/385 (79.9%) | 45 (21.0%)/171 (79.0%) | 0.323 |
AFP (< 20/20–400/ > 400 ng/mL) | 157 (32.6%)/119 (24.7%)/206 (42.7%) | 68 (31.6%)/54 (25.1%)/94 (43.3%) | 0.966 |
NEU (> 3.56/ ≤ 3.56 × 109/L) | 228 (47.4%)/254 (52.6%) | 99 (46.0%)/117 (54.0%) | 0.741 |
LYM (> 1.1/ ≤ 1.1 × 109/L) | 362 (75.1%)/120 (24.9%) | 171 (79.1%)/45 (20.9%) | 0.255 |
PLT (> 100/ ≤ 100 × 109/L) | 351 (72.8%)/131 (27.2%) | 143 (66.2%)/73 (33.8%) | 0.076 |
NLR (> 3/ ≤ 3) | 153 (31.8%)/329 (68.2%) | 47 (21.9%)/169 (78.1%) | 0.007 |
PLR (> 111/ ≤ 111) | 180 (37.3%)/302 (62.7%) | 59 (27.4%)/157 (72.6%) | 0.011 |
TBIL (> 28/ ≤ 28 μmol/L) | 15 (3.1%)/467 (96.9%) | 8 (3.7%)/208 (96.3%) | 0.689 |
ALT (> 50/ ≤ 50 IU/L) | 161 (33.4%)/321 (66.6%) | 76 (35.2%)/140 (64.8%) | 0.646 |
AST (> 40/ ≤ 40 IU/L) | 216 (44.8%)/266 (55.2%) | 101 (46.8%)/115 (53.2%) | 0.633 |
ALB (> 40/ ≤ 40 g/L) | 308 (63.9%)/174 (36.1%) | 131 (60.6%)/85 (39.4%) | 0.411 |
ALBI grade (1/2/3) | 343 (71.2%)/139 (28.8%)/0 (0%) | 136 (62.8%)/80 (37.2%)/0 (0%) | 0.025 |
GGT (> 60/ ≤ 60 IU/L) | 240 (49.8%)/242 (50.2%) | 114 (52.8%)/102 (47.2%) | 0.466 |
PT (> 12.8/ ≤ 12.8 s) | 119 (24.7%)/363 (75.3%) | 39 (17.9%)/177 (82.1%) | 0.344 |
INR (> 1.15/ ≤ 1.15) | 101 (21.0%)/381 (79.0%) | 50 (23.1%)/166 (76.9%) | 0.515 |
Fib (> 2/ ≤ 2 g/L) | 401 (83.2%)/81 (16.8%) | 173 (79.9%)/43 (20.1%) | 0.338 |
Tumor diameter (≤ 5/5–10/ > 10 cm) | 219 (45.4%)/199 (41.2%)/65 (13.4%) | 105 (48.4%)/89 (41.2%)/29 (13.4%) | 0.531 |
Tumor number (1/2/3) | 402 (83.4%)/58 (12.0%)/22 (4.6%) | 170 (78.6%)/37 (17.2%)/9 (4.2%) | 0.284 |
BCLC stage (A/B) | 409 (84.9%)/73 (15.1%) | 178 (82.3%)/38 (17.7%) | 0.399 |
Cirrhosis (present/absent) | 296 (61.4%)/186 (38.6%) | 153 (70.8%)/63 (29.2%) | 0.016 |
Differentiation (I + II/III + IV) | 279 (57.9%)/203 (42.1%) | 123 (56.9%)/93 (43.1%) | 0.816 |
MVI (present/absent) | 204 (42.3%)/278 (57.7%) | 86 (39.8%)/130 (60.2%) | 0.534 |
Satellite lesion (present/absent) | 72 (14.9%)/410 (85.1%) | 31 (14.4%)/185 (85.6%) | 0.840 |
Resection (anatomic/non-anatomic) | 250 (51.9%)/232 (48.1%) | 110 (50.9%)/106 (49.1%) | 0.818 |